High PTGS2 expression in post‐neoadjuvant chemotherapy‐treated oesophageal adenocarcinoma is associated with improved survival: a population‐based cohort study

High prostaglandin endoperoxide synthase‐2 (PTGS2) enzyme expression in oesophageal adenocarcinoma has been shown to independently predict poor prognosis; however, the evidence is inconsistent. The aim of this study was to investigated the association between PTGS2 expression and prognosis in patients with oesophageal adenocarcinoma.

[1]  M. Salto‐Tellez,et al.  Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma , 2018, Oncotarget.

[2]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[3]  Yanlong Yang,et al.  The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis , 2017, OncoTargets and therapy.

[4]  C. Menna,et al.  The esophagogastric junctional adenocarcinoma an increasing disease. , 2017, Journal of thoracic disease.

[5]  A. Gavin,et al.  Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study , 2017, Clinical and Translational Gastroenterology.

[6]  M. Salto‐Tellez,et al.  Building a 'Repository of Science': The importance of integrating biobanks within molecular pathology programmes. , 2016, European journal of cancer.

[7]  A. Shaw,et al.  Crizotinib resistance: implications for therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  K. Haustermans,et al.  Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Yingjie Shao,et al.  Analysis of the correlation between P53 and Cox-2 expression and prognosis in esophageal cancer , 2015, Oncology letters.

[10]  L. Bracci,et al.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer , 2013, Cell Death and Differentiation.

[11]  Shuji Ogino,et al.  How many molecular subtypes? Implications of the unique tumor principle in personalized medicine , 2012, Expert review of molecular diagnostics.

[12]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[13]  Douglas G. Altman,et al.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration , 2012, PLoS medicine.

[14]  C. Mariette,et al.  Oesophageal cancer: how radical should surgery be? , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  R. van Hillegersberg,et al.  Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma , 2012, Journal of Gastrointestinal Surgery.

[16]  C. Mariette,et al.  Oesophagogastric junction adenocarcinoma: which therapeutic approach? , 2011, The Lancet. Oncology.

[17]  P. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials , 2011, The Lancet.

[18]  R. DuBois,et al.  PROSTAGLANDINS AND CANCER , 2005, Gut.

[19]  Penny A. Johnson,et al.  Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus , 2006, BMC Cancer.

[20]  S. Baldus,et al.  High Cyclooxygenase-2 Expression Following Neoadjuvant Radiochemotherapy Is Associated with Minor Histopathologic Response and Poor Prognosis in Esophageal Cancer , 2005, Clinical Cancer Research.

[21]  R. Fitzgerald,et al.  Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells. , 2005, Carcinogenesis.

[22]  H. Hollema,et al.  Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma. , 2005, Cancer letters.

[23]  D I Watson,et al.  Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy. , 2004, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[24]  Yuan-yuan Li,et al.  Expression of cyclooxygenase‐2 (COX‐2) in human esophageal cancer and in vitro inhibition by a specific COX‐2 inhibitor, NS‐398 , 2004, Journal of gastroenterology and hepatology.

[25]  D. Vidaud,et al.  Cyclooxygenase‐2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma , 2003, Histopathology.

[26]  S. Tsujitani,et al.  Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas , 2003, Virchows Archiv.

[27]  C. Buskens,et al.  Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. , 2002, Gastroenterology.

[28]  Y. Doki,et al.  Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  R. DuBois,et al.  The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.

[30]  K. Schrör,et al.  Cyclooxygenase-2 expression in human esophageal carcinoma. , 1999, Cancer research.

[31]  R. DuBois,et al.  Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.

[32]  Siewert,et al.  [Cardia cancer: attempt at a therapeutically relevant classification]. , 1987, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[33]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[34]  E B Cox,et al.  Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. , 1986, Cancer research.

[35]  T. Westfall,et al.  ALTERATIONS IN THE , 1985 .